{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:07:02Z","timestamp":1789556822639,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"MSD Denmark"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Low-density lipoprotein cholesterol (LDL-C) goal attainment remains suboptimal among individuals with or at risk for atherosclerotic cardiovascular disease (ASCVD). We evaluated contemporary nationwide real-world LDL-C goal attainment in Denmark and the clinical and economic impact of simulated implementation of the 2020 Danish and 2019 European guidelines, which differ in LDL-C goal thresholds, treatment recommendations and access to advanced lipid-lowering therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this nationwide registry-based cohort study, we included all Danish residents aged 30\u201385 years classified as high-risk or very-high-risk for ASCVD, with LDL-C measurements between January 2022 and December 2023 and repeat measurements 6\u201315 months later. A simulation model estimated the impact of stepwise intensification of lipid-lowering therapy, including statins, ezetimibe and proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, on LDL-C goal attainment, preventable cardiovascular events and clinical event cost savings within the context of current Danish reimbursement restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 487 962 individuals (336 705 primary prevention and 151 257 secondary prevention), LDL-C goal attainment at follow-up in primary prevention was 39.8% under the Danish guideline and 15.1% under the European guideline and 18.8% in secondary prevention under both guidelines. With optimal implementation, attainment increased to 91.9% (primary) and 63.5% (secondary) under the Danish guideline, and to 75.8% (primary) and 96.8% (secondary) under the European guideline. Compared with real-world outcomes, implementation of the Danish guideline could annually prevent 589 strokes, 491 myocardial infarctions, 581 revascularisations and 196 cardiovascular deaths. Implementation of the European guideline would avert an additional 179 strokes, 156 myocardial infarctions, 166 revascularisations and 67 cardiovascular deaths, corresponding to annual clinical event cost savings of \u20ac15.8 million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early and broader adoption of combination lipid-lowering therapy could substantially improve LDL-C goal attainment, reduce cardiovascular events and generate meaningful healthcare cost savings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2026-004265","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:10:16Z","timestamp":1788786616000},"page":"e004265","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Nationwide LDL-C goal attainment in high-risk and very-high-risk patients in Denmark: real-world lipid management and simulated impact of guideline implementation"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-4609","authenticated-orcid":false,"given":"Abdullahi Ahmed","family":"Mohamed","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital Gentofte, Hellerup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogina","family":"Rached","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Roesgaard","family":"Kants\u00f8","sequence":"additional","affiliation":[{"name":"MSD Denmark, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Theisen","family":"Honore","sequence":"additional","affiliation":[{"name":"MSD Denmark, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Kobber\u00f8","family":"Lauridsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Fijolek","sequence":"additional","affiliation":[{"name":"MSD Denmark, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-402X","authenticated-orcid":false,"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Capital Region of Denmark, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026091603502737000_13.2.e004265.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.005"},{"key":"2026091603502737000_13.2.e004265.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.07.059"},{"key":"2026091603502737000_13.2.e004265.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.017"},{"key":"2026091603502737000_13.2.e004265.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026091603502737000_13.2.e004265.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.03.014"},{"key":"2026091603502737000_13.2.e004265.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"2026091603502737000_13.2.e004265.7","doi-asserted-by":"crossref","first-page":"131857","DOI":"10.1016\/j.ijcard.2024.131857","article-title":"Monitoring and treatment of hypercholesterolemia after an atherosclerotic cardiovascular disease event in Denmark from 2015 to 2020","volume":"402","author":"Hoe","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026091603502737000_13.2.e004265.8","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3390\/jcm12093187","article-title":"Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study","volume":"12","author":"Barrios","year":"2023","journal-title":"JCM"},{"key":"2026091603502737000_13.2.e004265.9","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"2026091603502737000_13.2.e004265.10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiolog"},{"key":"2026091603502737000_13.2.e004265.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2026091603502737000_13.2.e004265.12","unstructured":"Forebyggelse af hjertesygdom . Dansk cardiologisk selskab. Available: https:\/\/www.cardio.dk\/forebyggelse [Accessed 3 Dec 2025]."},{"key":"2026091603502737000_13.2.e004265.13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2147\/CLEP.S471335","article-title":"Cardiovascular Data Quality in the Danish National Patient Registry (1977-2024): A Systematic Review","volume":"16","author":"Lund","year":"2024","journal-title":"Clin Epidemiol"},{"key":"2026091603502737000_13.2.e004265.14","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A , Schmidt SAJ , Wallach-Kildemoes H , et al . Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol 2016. doi:10.1093\/ije\/dyw213","DOI":"10.1093\/ije\/dyw213"},{"key":"2026091603502737000_13.2.e004265.15","doi-asserted-by":"crossref","unstructured":"Arendt JFH , Hansen AT , Ladefoged SA , et al . 2020 Existing Data Sources in Clinical Epidemiology: Laboratory Information System Databases in Denmark.","DOI":"10.2147\/CLEP.S245060"},{"key":"2026091603502737000_13.2.e004265.16","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeab015","article-title":"Prediction of first cardiovascular disease event in 2.9 million individuals using Danish administrative healthcare data: a nationwide, registry-based derivation and validation study","volume":"1","author":"Christensen","year":"2021","journal-title":"Eur Heart J Open"},{"key":"2026091603502737000_13.2.e004265.17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026091603502737000_13.2.e004265.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100670","article-title":"Monte Carlo simulations to meet the ESC recommended low-density lipoprotein cholesterol targets","volume":"31","author":"Deo","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026091603502737000_13.2.e004265.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100665","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026091603502737000_13.2.e004265.20","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"The Lancet"},{"key":"2026091603502737000_13.2.e004265.21","doi-asserted-by":"crossref","first-page":"101125","DOI":"10.1016\/j.vhri.2025.101125","article-title":"Healthcare Costs of Myocardial Infarction in Denmark: A Nation-Wide Registry-Based Cohort Study","volume":"48","author":"Jensen","year":"2025","journal-title":"Value Health Reg Issues"},{"key":"2026091603502737000_13.2.e004265.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-015-1100-0","article-title":"Cost of stroke: a controlled national study evaluating societal effects on patients and their partners","volume":"15","author":"Jennum","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2026091603502737000_13.2.e004265.23","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.849942","article-title":"Cost-Effectiveness in Patients Undergoing Revascularization of Chronic Total Occluded Coronary Arteries-A Cohort Study","volume":"9","author":"Holck","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026091603502737000_13.2.e004265.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad583"},{"key":"2026091603502737000_13.2.e004265.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"2026091603502737000_13.2.e004265.26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12325-019-0879-1","article-title":"Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study","volume":"36","author":"Petrov","year":"2019","journal-title":"Adv Ther"},{"key":"2026091603502737000_13.2.e004265.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286376","article-title":"Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study","volume":"18","author":"Ersb\u00f8ll","year":"2023","journal-title":"PLoS One"},{"key":"2026091603502737000_13.2.e004265.28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020395","article-title":"Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus","volume":"10","author":"Malmborg","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026091603502737000_13.2.e004265.29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"},{"key":"2026091603502737000_13.2.e004265.30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ehjqcco\/qcac009","article-title":"Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study","volume":"8","author":"Ray","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026091603502737000_13.2.e004265.31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacl.2022.05.069","article-title":"Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials","volume":"16","author":"Schludi","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2026091603502737000_13.2.e004265.32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026091603502737000_13.2.e004265.33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026091603502737000_13.2.e004265.34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14744\/AnatolJCardiol.2022.2012","article-title":"How Did the Updated 2019 European Society of Cardiology\/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study","volume":"27","author":"Ba\u015faran","year":"2023","journal-title":"Anatol J Cardiol"},{"key":"2026091603502737000_13.2.e004265.35","doi-asserted-by":"crossref","unstructured":"Katzmann JL , Becker C , Bilitou A , et al . n.d. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. PLoS ONE 17:e0276898. doi:10.1371\/journal.pone.0276898","DOI":"10.1371\/journal.pone.0276898"},{"key":"2026091603502737000_13.2.e004265.36","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091603502737000_13.2.e004265.37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2525"},{"key":"2026091603502737000_13.2.e004265.38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0000000000001345","article-title":"Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis","volume":"81","author":"Ennezat","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026091603502737000_13.2.e004265.39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacl.2026.02.006","article-title":"Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis","volume":"20","author":"Kalra","year":"2026","journal-title":"J Clin Lipidol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2026-004265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:50:52Z","timestamp":1789555852000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2026-004265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/openhrt-2026-004265"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2026-004265","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}